Company: MYSEW
Filing Date: 2025-02-10
Form Type: 424B5
Source: 0001213900-25-011767
Chunk: 22

Company: Myseum, Inc.
Filing Date: 2025-02-10
Form: 424B5
Chunk 22
---
 common stock reserved for future issuance under our 2021 Omnibus Equity Incentive 
 Plan; and                                                                                   |

| ● | 67,385                                                                                        
 shares of our common stock issuable upon the exercise of outstanding warrants as of September 
 30, 2024, at a weighted-average exercise price of $49.80 per share.                           |

<div align='center'>S-12

PLAN OF DISTRIBUTION</div>

We may issue and sell shares
of our common stock from time to time under the Sales Agreement through Benchmark, acting as sales agent, subject to certain limitations,
having an aggregate gross sales price of up to $6,000,000. Sales of shares of our common stock, if any, under this prospectus supplement
and the accompanying prospectus may be made by any method that is deemed to be an “at the market offering” as defined in Rule
415(a)(4) promulgated under the Securities Act, including sales made directly on or through Nasdaq or on any other existing trading market
for our common stock.

Each time we wish to issue
and sell any shares of our common stock under the Sales Agreement, we will notify Benchmark of the aggregate number of shares to be sold,
the dates on which such sales are requested to be made, any limitation on the number of shares to be sold in any one day, any minimum
price below which sales may not be made, and other sales parameters as we deem appropriate. Once we have so instructed Benchmark, unless
Benchmark declines to accept the terms of such notice, Benchmark has agreed to use its commercially reasonable efforts consistent with
its normal trading and sales practices to sell such shares of common stock up to the amount specified on such terms. The obligations of
Benchmark under the Sales Agreement to sell shares of our common stock are subject to a number of conditions that we must meet.

The settlement for sales of
common stock between us and Benchmark is generally anticipated to occur on the first trading day following the date on which the sale
was made. Sales of our common stock as contemplated in this prospectus will be settled through the facilities of The Depository Trust Company or by such other means as we and Benchmark may agree upon. There
is no arrangement for funds to be received in an escrow, trust or similar arrangement.

We have agreed to pay Benchmark
a commission of 4.0% of the aggregate gross proceeds we receive from each sale of our common stock sold through Benchmark pursuant to
the Sales Agreement; provided however, that